Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: EXAS stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/S.
Implied fair value · at EXAS's multiple
Needs EXAS P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXAS FY 2025 (ended Dec 31, 2025) · VNDA FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
EXACT SCIENCES CORP · implied price per share
Bear
$0.03
Base
$0.03
Bull
$0.04
VANDA PHARMACEUTICALS INC. · implied price per share
Bear
-$5.92
Base
-$6.96
Bull
-$8.01
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
0.24x
Net debt / EBITDA
Leverage against operating earnings
-12.66x
0.82x
Cash and equivalents
Liquid reserves on the balance sheet
$964.71M
$185.77M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
OPKO HEALTH, INC.
EXAS vs OPK
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
SUPERNUS PHARMACEUTICALS, INC.
EXAS vs SUPN
CATALYST PHARMACEUTICALS, INC.
EXAS vs CPRX
Harmony Biosciences Holdings, Inc.
EXAS vs HRMY
ELI LILLY & Co
EXAS vs LLY
INCYTE CORP
EXAS vs INCY
Sarepta Therapeutics, Inc.
EXAS vs SRPT
$50.83M
$78.18M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe EXAS can sustain double-digit revenue growth while continuing to improve margins, then favor EXAS because its revenue scale, gross margin, and balance sheet are materially stronger than VNDA’s.
VNDA-implied valuation range for EXAS is wide, from $1.51 to $24.52, with the current implied price at the top of that range. That suggests the market is valuing EXAS more aggressively than VNDA, likely because EXAS has much stronger revenue scale, growth, and profitability metrics.
Supporting Metrics
